| zilovertamab (UC-961) / Oncternal Therap |
2022-001547-25: A Phase 3 study of Zilovertamab in addition to Ibrutinib in Subjects with Relapsed or Refractory Mantle Cell Lymphoma Estudio en fase III de zilovertamab en combinación con ibrutinib en pacientes con linfoma de células del manto recidivante o resistente |
|
|
| Ongoing | 3 | 365 | Europe | Zilovertamab, Ibrutinib, Zilovertamab, PCI-32765, Solution for infusion, Capsule, hard | Oncternal Therapeutics, Inc, Oncternal Therapeutics, Inc | Relapsed or Refractory Mantle Cell Lymphoma Linfoma de células del manto recidivante o resistente, Mantle Cell Lymphoma Linfoma de células del manto, Diseases [C] - Cancer [C04] | | | | |
| Withdrawn | 3 | 365 | NA | Zilovertamab, Cirmtuzumab, UC961, Ibrutinib, Imbruvica, Placebo | Oncternal Therapeutics, Inc, Pharmacyclics LLC. | Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders, Lymphatic Diseases, Immunoproliferative Disorders, Immune System Diseases, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell | 11/26 | 12/26 | | |
NCT05555706: Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer |
|
|
| Recruiting | 2/3 | 450 | RoW | B013+Nab-Paclitaxel | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Triple Negative Breast Cancer (TNBC) | 06/25 | 12/26 | | |
NCT06434610: A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. |
|
|
| Recruiting | 2 | 90 | RoW | B013, Paclitaxel, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Platinum-resistant Recurrent Ovarian Cancer | 12/26 | 12/26 | | |
NCT04501939: Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax |
|
|
| Active, not recruiting | 2 | 5 | US | Cirmtuzumab, Zilovertamab, Venetoclax, VENCLEXTA | University of California, San Diego, Oncternal Therapeutics, Inc | Chronic Lymphocytic Leukemia | 07/25 | 07/25 | | |
NCT03088878: A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies |
|
|
| Completed | 1/2 | 95 | US | Cirmtuzumab (2-16 kg/mg) plus Ibrutinib, UC-961, Imbruvica, Cirmtuzumab (300mg) plus Ibrutinib, Cirmtuzumab (600 mg) plus ibrutinib, Cirmtuzumab (RDR) plus ibrutinib, Cirmtuzumab plus ibrutinib, Ibrutinib alone | Oncternal Therapeutics, Inc, California Institute for Regenerative Medicine (CIRM), University of California, San Diego, Pharmacyclics LLC. | B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma | 09/24 | 09/24 | | |
| Recruiting | 1b | 156 | US | Cirmtuzumab followed by Cirmtuzumab plus ibrutinib, UC-961, Imbruvica, Cirmtuzumab plus ibrutinib, Ibrutinib | Oncternal Therapeutics, Inc, University of California, San Diego, California Institute for Regenerative Medicine (CIRM) | B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma | 04/19 | 12/22 | | |
NCT02776917: Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer |
|
|
| Completed | 1 | 22 | US | Cirmtuzumab + Paclitaxel, UC-961, Taxol | Barbara Parker, MD, Oncternal Therapeutics, Inc | Breast Neoplasms | 07/21 | 02/24 | | |
CirmD, NCT05156905: Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer |
|
|
| Terminated | 1 | 6 | US | Cirmtuzumab, Docetaxel | University of California, San Diego | Metastatic Castration-resistant Prostate Cancer | 10/24 | 10/24 | | |
